How to Choose a Longevity Testing Partner: A Buyer's Guide for Functional Medicine Clinics

Choosing a longevity testing partner means evaluating which biomarker, onboarding model, and clinical support structure will actually change how you treat patients, not just what you can sell them. Most functional medicine clinics can already report a patient's cholesterol, HbA1c, or hormone panel, but few can tell that same patient whether their immune system is aging faster than it should, or whether the HRT protocol, peptide therapy, or lifestyle overhaul they prescribed actually changed anything at the biological level. 

This article is written for clinics and integrative providers weighing biological age testing options, including glycan-based tests, against epigenetic clocks, DNA panels, and generic blood work, and focuses on what to ask a testing partner before signing, how the onboarding and commercial model actually works, and whether a biomarker can close the gap between "we treated you" and "we can prove it worked." 

For deeper background on the clinical case for this category, see our guide to GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

What should a longevity testing partner actually provide?

A longevity testing partner should supply a validated biomarker, a repeatable testing workflow, and clinical support that helps you interpret results with patients, not just a lab report. A partnership at this level typically includes simple finger-prick blood spot test kits shipped to the practice or directly to patients, a detailed report with guidance on recommended next steps, and access to educational resources such as one-on-one results interpretation sessions, alongside ad hoc support for sales and marketing. Before signing with any provider, confirm what happens after the blood draw: who interprets the result, who trains your staff, whether interpretation sessions are included or offered as an add-on, and whether patient-facing education is built into the cost or billed separately. 

What is glycan-based biological age testing, and how does it differ from DNA tests?

Glycan-based biological age testing measures IgG glycosylation, the pattern of complex sugars called glycans attached to Immunoglobulin G antibodies, to quantify how fast a patient's immune system is aging relative to their chronological age. Unlike DNA testing, which reveals fixed genetic potential, biological age measured through glycans is dynamic. It changes with lifestyle, hormones, and treatment, which means a patient can actually move the number. Chronological age is simply time elapsed since birth and advances at the same rate for everyone; biological age reflects physiological health and functional capacity and is shaped by lifestyle, genetics, and environment. Because aging is the single biggest risk factor for chronic disease, a biomarker that reveals how fast a patient's biology is actually aging gives a clinic a lever that a static genetic readout cannot.

"In [an earlier] study, the median error was around four years, but in our study, when testing an external data set, the median error was 1.7 years. In lay terms, this means we were able to predict age to within 1.7 years."

— Prof. Riccardo Marioni, Chair of Molecular Epidemiology of Ageing, University of Edinburgh 

Can this replace the blood panels my clinic already runs?

No, and it shouldn't try to. Glycan-based biological age testing is designed to sit alongside comprehensive blood panels as a distinct inflammation layer, not to duplicate existing diagnostics. Standard panels capture metabolic, lipid, and hormone status at a single point in time. IgG glycosylation gives practitioners a stable, repeatable marker of immune aging that those panels don't surface. When evaluating a testing partner, ask whether their product is positioned as a replacement for your current workup or as an addition to it. A partner that frames itself as an added layer, not a competing panel, is easier to integrate into an existing patient journey without disrupting what already works.

How do I know if a biological age test is scientifically credible?

A credible biological age test should be built on a biomarker with established scientific validity and clinical utility, not just marketing claims. The American Federation for Aging Research has outlined what an ideal aging biomarker should do: predict future health outcomes better than chronological age alone, produce consistent and repeatable results, track a core aging process, and apply across both human and research settings. Different tests rely on different signals, including telomere length, DNA methylation patterns, and glycans, and their scientific validity, clinical utility, and price points vary considerably. Before signing a partnership agreement, ask the vendor to show peer-reviewed publications behind their biomarker, not just internal white papers, and check whether independent researchers have used the same test in published studies.

Why do aesthetic and integrative practices specifically add this kind of testing?

Aesthetic and longevity-adjacent practices add glycan-based testing to differentiate their offering and deepen patient relationships through longitudinal tracking. Practitioners report that it lets them integrate aesthetics with longevity care, building deeper patient relationships through personalized tracking and ongoing support, backed by science used in peer-reviewed research on aging and inflammation. This matters commercially as well as clinically: a test that requires a retest cadence creates a natural reason for a patient to return, rather than a one-off diagnostic that gets filed away. If your practice already blends aesthetic and wellness services, ask a prospective testing partner how their retest workflow is structured and whether it supports a recurring visit model.

What does the onboarding process for a testing partnership actually look like?

Onboarding should give a clinic a validated biological age test built on established biomarkers, without requiring the clinic to build its own lab or interpretation infrastructure from scratch. Adding glycan biomarker testing to an existing practice typically works through a self-service dashboard, finger-prick test kits shipped to the practice or directly to patients, and clinical education support. The goal of the partnership is to help practitioners track whether a patient's interventions, whether HRT, a peptide protocol, or a lifestyle change, are working at a biological level. When comparing vendors, ask for a walkthrough of the dashboard, sample patient reports, and the specific clinical education materials provided at onboarding, not just a sales deck. 

Is this test diagnostic, and what should I tell patients it measures?

No. Glycan-based biological age testing is not a diagnostic tool; it is a biomarker for tracking immune aging and chronic inflammation over time, meant to be interpreted alongside clinical history rather than used to diagnose disease. Patients should understand that a result reflects the current state of inflammatory biology and how it shifts with intervention, not a screening for a specific condition. 

"Normally, our early warning is a heart attack, a stroke, or a diabetes diagnosis, but by then it's usually beyond the point of no return. If you catch it early, if the biomarkers are moving in that direction but there's still no tissue damage, you can fix it, and hopefully you'll never develop the disease."

— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge

When briefing patients, frame the test as a way to measure whether a chosen protocol is working, not as a substitute for standard diagnostic workups. Any partner that markets its product using diagnostic language such as "detects" or "screens for disease" should be a flag during vendor evaluation, since that framing sits outside what any validated aging biomarker, glycan-based or otherwise, is designed to do.

What should I ask before committing to a testing partnership?

Ask what happens at each stage: sample logistics, turnaround time, dashboard access, patient-facing report design, and the specific support given for result interpretation calls. Confirm whether the partner's biomarker has independent peer-reviewed validation, what its retest interval looks like for lifestyle versus medical interventions, and whether pricing scales with patient volume or requires upfront inventory commitments. Ask how the partner supports your team's clinical education, since a biomarker is only as useful as your staff's ability to explain it credibly to a skeptical, informed patient. Finally, confirm the partnership includes marketing and sales support, since a differentiated offering needs to be communicated clearly to existing and prospective patients.

If your clinic is ready to evaluate a longevity testing partnership in more depth, visit the GlycanAge for Healthcare Providers page to review the partnership model, clinical use cases, and onboarding process, or start a partner application directly through Partner Sign-Up.

Give your practice a validated, repeatable way to prove your interventions are working, before your competitors do. 

Explore Partnership Options →

External sources

• https://www.afar.org/imported/AFAR_BIOMARKERS_OF_AGING_2016.pdf —  American Federation for Aging Research: Biomarkers of Aging 

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4049143/ — Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci. 2014;69(7):779-789.

• https://pubmed.ncbi.nlm.nih.gov/19726492/ — Gornik O, Wagner J, Pučić M, Knežević A, Redžić I, Lauc G. Stability of N-glycan profiles in human plasma. Glycobiology. 2009;19(12):1547-1553.